Literature DB >> 21154805

The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Krishna Mohan Bajjuri1, Yuan Liu, Cheng Liu, Subhash C Sinha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21154805      PMCID： PMC3549592          DOI： 10.1002/cmdc.201000478

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  46 in total

1.  Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone.

Authors:  Bénédicte Manoury; Daniela Mazzeo; Dongtao Ni Li; Jeremy Billson; Kylie Loak; Philippe Benaroch; Colin Watts
Journal:  Immunity       Date:  2003-04       Impact factor: 31.745

2.  Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.

Authors:  Lian-Sheng Li; Christoph Rader; Masayuki Matsushita; Sanjib Das; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

3.  MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research.

Authors:  James M Rae; Chad J Creighton; Jeanne M Meck; Bassem R Haddad; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

4.  Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.

Authors:  F M de Groot; A C de Bart; J H Verheijen; H W Scheeren
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

5.  An efficient chemical approach to bispecific antibodies and antibodies of high valency.

Authors:  Julia I Gavrilyuk; Ulrich Wuellner; Syed Salahuddin; Rajib K Goswami; Subhash C Sinha; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

6.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

7.  Duocarmycin-based prodrugs for cancer prodrug monotherapy.

Authors:  Lutz F Tietze; Heiko J Schuster; Kianga Schmuck; Ingrid Schuberth; Frauke Alves
Journal:  Bioorg Med Chem       Date:  2008-05-07       Impact factor: 3.641

8.  Protease-activated "prodrugs" for cancer chemotherapy.

Authors:  P L Carl; P K Chakravarty; J A Katzenellenbogen; M J Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases).

Authors:  Karen Ellis James; Marion G Götz; Conor R Caffrey; Elizabeth Hansell; Wendy Carter; Alan J Barrett; James H McKerrow; James C Powers
Journal:  Biol Chem       Date:  2003-12       Impact factor: 3.915

Review 10.  Potent antibody drug conjugates for cancer therapy.

Authors:  Peter D Senter
Journal:  Curr Opin Chem Biol       Date:  2009-05-04       Impact factor: 8.822
View more
  21 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes.

Authors:  Marcin Poreba; Rigmor Solberg; Wioletta Rut; Ngoc Nguyen Lunde; Paulina Kasperkiewicz; Scott J Snipas; Marko Mihelic; Dusan Turk; Boris Turk; Guy S Salvesen; Marcin Drag
Journal:  Cell Chem Biol       Date:  2016-07-28       Impact factor: 8.116

3.  Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.

Authors:  Oran Erster; Jerry M Thomas; Juliana Hamzah; Abeer M Jabaiah; Jennifer A Getz; Tobias D Schoep; Sejal S Hall; Erkki Ruoslahti; Patrick S Daugherty
Journal:  J Control Release       Date:  2012-05-23       Impact factor: 9.776

4.  Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile.

Authors:  Elfriede Dall; Hans Brandstetter
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-12-24

5.  Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.

Authors:  Susan Matthew; Qi-Yin Chen; Ranjala Ratnayake; Charles S Fermaintt; Daniel Lucena-Agell; Francesca Bonato; Andrea E Prota; Seok Ting Lim; Xiaomeng Wang; J Fernando Díaz; April L Risinger; Valerie J Paul; Maria Ángela Oliva; Hendrik Luesch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

6.  Functional imaging of legumain in cancer using a new quenched activity-based probe.

Authors:  Laura E Edgington; Martijn Verdoes; Alberto Ortega; Nimali P Withana; Jiyoun Lee; Salahuddin Syed; Michael H Bachmann; Galia Blum; Matthew Bogyo
Journal:  J Am Chem Soc       Date:  2012-12-18       Impact factor: 15.419

7.  Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness.

Authors:  Yoshio Ohno; Jun Nakashima; Miki Izumi; Makoto Ohori; Takeshi Hashimoto; Masaaki Tachibana
Journal:  World J Urol       Date:  2012-11-03       Impact factor: 4.226

8.  Expression of legumain correlates with prognosis and metastasis in gastric carcinoma.

Authors:  Pengtao Guo; Zhi Zhu; Zhe Sun; Zhenning Wang; Xinyu Zheng; Huimian Xu
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

Review 9.  Peptide-Drug Conjugates with Different Linkers for Cancer Therapy.

Authors:  Mona Alas; Azam Saghaeidehkordi; Kamaljit Kaur
Journal:  J Med Chem       Date:  2020-12-31       Impact factor: 7.446

10.  Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery.

Authors:  Jessica L Crisp; Elamprakash N Savariar; Heather L Glasgow; Lesley G Ellies; Michael A Whitney; Roger Y Tsien
Journal:  Mol Cancer Ther       Date:  2014-04-15       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.